Cargando…

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer

As conventional biomarkers for defining breast cancer (BC) subtypes are not always capable of predicting prognosis, search for new biomarkers which can be easily detected by liquid biopsy is ongoing. It has long been known that cell-free DNA (CF-DNA) could be a promising diagnostic and prognostic ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maltoni, Roberta, Casadio, Valentina, Ravaioli, Sara, Foca, Flavia, Tumedei, Maria Maddalena, Salvi, Samanta, Martignano, Filippo, Calistri, Daniele, Rocca, Andrea, Schirone, Alessio, Amadori, Dino, Bravaccini, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369991/ https://www.ncbi.nlm.nih.gov/pubmed/28186965 http://dx.doi.org/10.18632/oncotarget.15120

Ejemplares similares

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications
por: Martignano, Filippo, et al.
Publicado: (2016)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients
por: Salvi, Samanta, et al.
Publicado: (2015)

The current role of telomerase in the diagnosis of bladder cancer
por: Bravaccini, Sara, et al.
Publicado: (2009)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
por: Maltoni, Roberta, et al.
Publicado: (2020)

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach
por: Gurioli, Giorgia, et al.
Publicado: (2016)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
por: Bravaccini, Sara, et al.
Publicado: (2018)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study
por: Casadio, Valentina, et al.
Publicado: (2013)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
por: Bravaccini, Sara, et al.
Publicado: (2020)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology
por: Ravaioli, Sara, et al.
Publicado: (2016)

Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
por: Pirini, Francesca, et al.
Publicado: (2023)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
por: Rocca, Andrea, et al.
Publicado: (2018)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
por: Rocca, Andrea, et al.
Publicado: (2017)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
por: Cortesi, Michela, et al.
Publicado: (2021)

Evaluating the appropriateness of chemotherapy in a low‐resource cancer centre in sub‐Saharan Africa
por: Serra, Patrizia, et al.
Publicado: (2019)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
por: Bravaccini, Sara, et al.
Publicado: (2019)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Bravaccini, Sara, et al.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer
por: Salvi, Samanta, et al.
Publicado: (2014)

New Biomarkers to Predict the Evolution of In Situ Breast Cancers
por: Bravaccini, S., et al.
Publicado: (2014)

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
por: Bravaccini, Sara, et al.
Publicado: (2018)

Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
por: Maltoni, Roberta, et al.
Publicado: (2021)

Cell-free DNA as a diagnostic marker for cancer: current insights
por: Salvi, Samanta, et al.
Publicado: (2016)

DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach
por: Casadio, Valentina, et al.
Publicado: (2013)

Usefulness of Immunological Detection of the Human Telomerase Reverse Transcriptase
por: Volpi, Annalisa, et al.
Publicado: (2005)

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer
por: Molinari, Chiara, et al.
Publicado: (2016)

Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report
por: Maltoni, Roberta, et al.
Publicado: (2020)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ce8t435t9jdtrr1p1r140s5t0